Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 
Search Results



Your search returned 1870 record(s).

Page 142 of 187  |  Previous Page   |  Next Page

Cancer Type:   Sort By:

This Search was Made Possible by:


  Survival: Patients: Toxicity: Treatment: Hospital: Country: Date:
1411 8.3 months GBM 5 Biologic therapy
Chemotherapy
Duke University Medical Center United States 10/2011
Treatment Details: Patients: This phase II study involved 40 glioblastoma patients who had not received prior treatment with bevacizumab. The median patient age was 51 years and 75% were male. Treatment:
 
1412 8.3 months Liver 4 Chemotherapy
Gustave-Roussy France 4/2014
Treatment Details: Patients: This study involved 40 advanced hepatocellular carcinoma patients who had received prior biologic anti-angiogenic therapy. The average patient age was 52 years and 34 were male.
 
1413 8.3 months Advanced urothelial cancer 4 Biologic therapy
Memorial Sloan-Kettering Cancer Center United States 4/2013
Treatment Details: Patients: This phase 2 study involved 45 advanced urothelial carcinoma patients. The median patient age was 66 years and 69% were male. Treatment: Patients were treated with the biolog
 
1414 8.3 months GBM 4 Radiation
Linköping University Sweden 9/2012
Treatment Details: Patients: This phase 3 study involved newly diagnosed glioblastoma patients, all older than 60 years, who were divided into three separate treatment groups. Group A was composed of 93 pati
 
1415 8.3 months Newly diagnosed GBM Radiation
Naval Medical Center Portsmouth United States 10/2002
Treatment Details: Patients: This study involved a total of 67 patients, 45 of whom had glioblastoma multiforme. Glioblastoma patients were divided into two groups: 17 patients in Group A who were treated at
 
1416 8.3 months Advanced colorectal cancer 4 Chemotherapy
University of Chicago United States 6/2004
Treatment Details: Patients: This Phase II trial involved 25 patients with advanced colorectal cancer who had disease progression (increase in tumor size or tumor spread) after being treated with irinotecan-5-
 
1417 8.3 months Advanced NSCLC 4 Chemotherapy
Istituto Nazionale dei Tumori Italy 3/2003
Treatment Details: Patients: This Phase III trial involved 698 patients with advanced non-small-cell lung cancer. All patients were age 70 or older. Patients were divided into three groups. Group 1 comprise
 
1418 8.3 months Advanced colorectal cancer 4 Chemotherapy
University of Chicago United States 6/2004
Treatment Details: Patients: This Phase II trial involved 25 patients with advanced colorectal cancer who had disease progression (increase in tumor size or tumor spread) after being treated with irinotecan-5-
 
1419 8.3 months Recurrent glioblastoma multiforme 5 Chemotherapy
MD Anderson Cancer Center United States 4/2008
Treatment Details: Patients: This phase II study involved 32 patients with recurrent glioblastoma multiforme. The median age was 46.5 years, ranging from 21 to 65. The majority, 75%, were men. Treatment:
 
1420 8.3 months Advanced NSCLC 4 Biologic therapy
Chemotherapy
Catalan Institute of Oncology Spain 2/2008
Treatment Details: Patients: This phase II study involved eighty-six patients with advanced non-small-cell lung cancer that expressed EGFR. These patients ranged in age from 33 to 74 years old, and there wer
 
Page 142 of 187  | Previous Page  | Next Page